← Search & browse all drugs
NERVOUS SYSTEM › ANTI-PARKINSON DRUGS › DOPAMINERGIC AGENTS › Monoamine oxidase B inhibitors
rasagiline
N04BD02
Forms & Strengths
- Oral tablets: 0.5 mg
- Oral tablets: 1 mg
Adult Dosing
- Idiopathic Parkinson's disease as initial monotherapy: 1 mg once daily
- Adjunct therapy to levodopa: 0.5 mg once daily, may be increased to 1 mg once daily if needed
Pediatric Dosing
- Safety and efficacy in pediatric patients have not been established
Indications
- Treatment of the signs and symptoms of idiopathic Parkinson's disease as initial monotherapy or as adjunct therapy to levodopa
Mechanism of Action
- Irreversible and selective inhibitor of monoamine oxidase type B (MAO-B), increasing extracellular levels of dopamine in the striatum
Contraindications
- Concomitant use with other MAO inhibitors (including other rasagiline, linezolid)
- Concomitant use with meperidine, tramadol, methadone, propoxyphene, and St. John's wort
- Concurrent use of dextromethorphan
- Moderate to severe hepatic impairment
Adverse Reactions
- Dyskinesia
- Orthostatic hypotension
- Fall
- Arthralgia
- Headache
- Insomnia
- Depression
- Dry mouth
Drug Interactions
- MAO inhibitors and sympathomimetics: risk of hypertensive crisis
- Meperidine and opioid analgesics: risk of fatal CNS toxicity (serotonin syndrome)
- SSRIs, SNRIs, tricyclic antidepressants: risk of serotonin syndrome
- CYP1A2 inhibitors (e.g., ciprofloxacin): may increase rasagiline exposure
Curated Content: Needs Vetting Before Put to Clinical Use